One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
Undergoing progressive relaxation exercise training improved management of distress, physical symptoms, and psychological symptoms in patients receiving chemotherapy for lung cancer.
Aggregate out-of-pocket costs were $427,069.74 for patients who underwent lung cancer screening and downstream procedures.
The newly eligible population includes individuals aged 50 to 54 years, more women, and more racial and ethnic minority groups.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Most patients studied did not have thyroid labs obtained after immune checkpoint inhibitor treatment.
The approval was based on data from the phase 3 IMpower010 study.
The confirmed response rate was 27%, and the median progression-free survival was 5.5 months.
Life-space assessments may help older adults better understand how cancer treatment impacts their lives, authors say.
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
The technology could save patients from ineffective treatment, according to researchers.
The method involves DELFI, an approach that can detect many abnormalities in cfDNA through genome-wide analysis of fragmentation patterns.
African-American and Hispanic patients remain less likely than White patients to be eligible for lung cancer screening.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
PD-L1 expression and tumor mutational burden were not associated with survival.
Patients who received early palliative care had improvements in symptom control and mood over time.
The AI technology was tested on 1,179 patients in a lung screening trial.
Enrollment declined 43% from 2019 to 2020.
Factors associated with poor survival were advanced age and male sex.
The 12-month progression-free survival rate was superior in the lurbinectedin arm.